Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Chief Medical Officer | September 15, 2026 | September 15, 2026 |
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | CHIEF MEDICAL OFFICER | April 05, 2024 | April 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date September 15, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,771 |
Ending reported balance
After 2026-09-15 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 3,500 · Balance 36,218 Row 2 · 2026-09-15 · Exercise / conversion · Acquired 3,500 · Balance 39,718 Row 3 · 2026-09-15 · Sale · Disposed 2,384 · Balance 37,334 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.52 to $91.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Row 4 · 2026-09-15 · Sale · Disposed 3,150 · Balance 34,184 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.56 to $92.55, inclusive. Row 5 · 2026-09-15 · Sale · Disposed 1,366 · Balance 32,818 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.62 to $93.54, inclusive. Row 6 · 2026-09-15 · Sale · Disposed 100 · Balance 32,718 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.04 to $94.35, inclusive. Row 7 · 2026-09-15 · Sale · Disposed 947 · Balance 31,771 F6: These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.84 · Expires 2034-05-06 | Direct | 193,563 |
Reported balance
After 2026-09-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-15 · Exercise / conversion · Disposed 3,500 · Balance 193,563 F7: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. |
| Employee Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2034-07-14 | Direct | 164,992 |
Reported balance
After 2026-09-15 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-15 · Exercise / conversion · Disposed 3,500 · Balance 164,992 F8: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.52 to $91.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.56 to $92.55, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.62 to $93.54, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.04 to $94.35, inclusive.
F6: These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.
F7: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
F8: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
Tvardi Therapeutics, Inc.
Report date April 05, 2024 · Filed April 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,365 |
Reported balance
After 2024-04-05 transaction · row 1
1 source rowRow 1 · 2024-04-05 · Sale · Disposed 2,753 · Balance 53,365 F1: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on March 12, 2020 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on March 12, 2020 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 15, 2026 23:18 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000098 · form4.xml · derivative · entry 9 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,992 Underlying: Common Stock · 3,500 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:18 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000907654-26-000098 · form4.xml · derivative · entry 8 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,563 Underlying: Common Stock · 3,500 shares Expires 2034-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:18 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 947 | $95.71 | $90,637.37 |
DisclosureSEC source: 0000907654-26-000098 · form4.xml · nonDerivative · entry 7 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,771 F6 · kind: These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:18 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 100 | $94.22 | $9,421.72 |
DisclosureSEC source: 0000907654-26-000098 · form4.xml · nonDerivative · entry 6 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,718 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.04 to $94.35, inclusive. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:18 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 1,366 | $92.99 | $127,022.70 |
DisclosureSEC source: 0000907654-26-000098 · form4.xml · nonDerivative · entry 5 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,818 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.62 to $93.54, inclusive. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:18 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 3,150 | $92.03 | $289,889.78 |
DisclosureSEC source: 0000907654-26-000098 · form4.xml · nonDerivative · entry 4 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,184 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.56 to $92.55, inclusive. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:18 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 2,384 | $91.10 | $217,173.34 |
DisclosureSEC source: 0000907654-26-000098 · form4.xml · nonDerivative · entry 3 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,334 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.52 to $91.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:18 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0000907654-26-000098 · form4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:18 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $6.84 | $23,940.00 |
DisclosureSEC source: 0000907654-26-000098 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2026 Filed Aug 17, 2026 22:09 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000079 · form4.xml · derivative · entry 8 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,492 Underlying: Common Stock · 3,500 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| August 17, 2026 Filed Aug 17, 2026 22:09 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000907654-26-000079 · form4.xml · derivative · entry 7 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,063 Underlying: Common Stock · 3,500 shares Expires 2034-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| August 17, 2026 Filed Aug 17, 2026 22:09 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 2,480 | $112.56 | $279,154.26 |
DisclosureSEC source: 0000907654-26-000079 · form4.xml · nonDerivative · entry 6 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,718 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.34 to $112.86, inclusive. Read SEC document |
| August 17, 2026 Filed Aug 17, 2026 22:09 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 3,320 | $112.01 | $371,885.82 |
DisclosureSEC source: 0000907654-26-000079 · form4.xml · nonDerivative · entry 5 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,198 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.34 to $112.33, inclusive. Read SEC document |
| August 17, 2026 Filed Aug 17, 2026 22:09 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 300 | $110.52 | $33,155.01 |
DisclosureSEC source: 0000907654-26-000079 · form4.xml · nonDerivative · entry 4 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,518 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.27 to $111.00, inclusive. Read SEC document |
| August 17, 2026 Filed Aug 17, 2026 22:09 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 900 | $109.65 | $98,686.98 |
DisclosureSEC source: 0000907654-26-000079 · form4.xml · nonDerivative · entry 3 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,818 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.05 to $110.04, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Read SEC document |
| August 17, 2026 Filed Aug 17, 2026 22:09 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0000907654-26-000079 · form4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2026 Filed Aug 17, 2026 22:09 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $6.84 | $23,940.00 |
DisclosureSEC source: 0000907654-26-000079 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2026 Filed Jul 15, 2026 23:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000073 · form4.xml · derivative · entry 8 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,992 Underlying: Common Stock · 3,500 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| July 15, 2026 Filed Jul 15, 2026 23:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000907654-26-000073 · form4.xml · derivative · entry 7 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,563 Underlying: Common Stock · 3,500 shares Expires 2034-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| July 15, 2026 Filed Jul 15, 2026 23:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 300 | $87.25 | $26,175.99 |
DisclosureSEC source: 0000907654-26-000073 · form4.xml · nonDerivative · entry 6 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,718 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.25 to $87.26, inclusive. Read SEC document |
| July 15, 2026 Filed Jul 15, 2026 23:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 3,803 | $86.68 | $329,630.35 |
DisclosureSEC source: 0000907654-26-000073 · form4.xml · nonDerivative · entry 5 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,018 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.21 to $87.04, inclusive. Read SEC document |
| July 15, 2026 Filed Jul 15, 2026 23:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 2,497 | $85.86 | $214,385.43 |
DisclosureSEC source: 0000907654-26-000073 · form4.xml · nonDerivative · entry 4 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,821 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.21 to $86.20, inclusive. Read SEC document |
| July 15, 2026 Filed Jul 15, 2026 23:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 400 | $84.37 | $33,746.00 |
DisclosureSEC source: 0000907654-26-000073 · form4.xml · nonDerivative · entry 3 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,318 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.87 to $84.57, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Read SEC document |
| July 15, 2026 Filed Jul 15, 2026 23:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0000907654-26-000073 · form4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2026 Filed Jul 15, 2026 23:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $6.84 | $23,940.00 |
DisclosureSEC source: 0000907654-26-000073 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2026 Filed Jun 15, 2026 22:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000063 · form4.xml · derivative · entry 8 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,492 Underlying: Common Stock · 3,500 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| June 15, 2026 Filed Jun 15, 2026 22:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000907654-26-000063 · form4.xml · derivative · entry 7 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,063 Underlying: Common Stock · 3,500 shares Expires 2034-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| June 15, 2026 Filed Jun 15, 2026 22:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 947 | $69.69 | $65,996.43 |
DisclosureSEC source: 0000907654-26-000063 · form4.xml · nonDerivative · entry 6 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,718 F6 · kind: These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document |
| June 15, 2026 Filed Jun 15, 2026 22:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 300 | $70.62 | $21,186.99 |
DisclosureSEC source: 0000907654-26-000063 · form4.xml · nonDerivative · entry 5 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,665 F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.29 to $70.79, inclusive. Read SEC document |
| June 15, 2026 Filed Jun 15, 2026 22:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 5,064 | $69.42 | $351,547.44 |
DisclosureSEC source: 0000907654-26-000063 · form4.xml · nonDerivative · entry 4 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,965 F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.98 to $69.83, inclusive. Read SEC document |
| June 15, 2026 Filed Jun 15, 2026 22:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 1,636 | $68.38 | $111,876.06 |
DisclosureSEC source: 0000907654-26-000063 · form4.xml · nonDerivative · entry 3 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,029 F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.97 to $68.96, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (5) to this Form 4. Read SEC document |
| June 15, 2026 Filed Jun 15, 2026 22:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0000907654-26-000063 · form4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2026 Filed Jun 15, 2026 22:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $6.84 | $23,940.00 |
DisclosureSEC source: 0000907654-26-000063 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 288 shares acquired under the Oruka Therapeutics, Inc. stock purchase plan on June 8, 2026. Read SEC document |
| May 15, 2026 Filed May 16, 2026 00:17 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000039 · form4.xml · derivative · entry 7 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,992 Underlying: Common Stock · 3,500 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| May 15, 2026 Filed May 16, 2026 00:17 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000907654-26-000039 · form4.xml · derivative · entry 6 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,563 Underlying: Common Stock · 3,500 shares Expires 2034-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| May 15, 2026 Filed May 16, 2026 00:17 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 100 | $63.52 | $6,352.00 |
DisclosureSEC source: 0000907654-26-000039 · form4.xml · nonDerivative · entry 5 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,377 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. Read SEC document |
| May 15, 2026 Filed May 16, 2026 00:17 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 2,100 | $62.42 | $131,088.30 |
DisclosureSEC source: 0000907654-26-000039 · form4.xml · nonDerivative · entry 4 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,477 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.02 to $62.89, inclusive. Read SEC document |
| May 15, 2026 Filed May 16, 2026 00:17 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 4,800 | $61.56 | $295,494.72 |
DisclosureSEC source: 0000907654-26-000039 · form4.xml · nonDerivative · entry 3 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,577 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.93 to $61.90, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| May 15, 2026 Filed May 16, 2026 00:17 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0000907654-26-000039 · form4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 16, 2026 00:17 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $6.84 | $23,940.00 |
DisclosureSEC source: 0000907654-26-000039 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:45 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000035 · form4.xml · derivative · entry 7 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,492 Underlying: Common Stock · 3,500 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:45 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000907654-26-000035 · form4.xml · derivative · entry 6 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,063 Underlying: Common Stock · 3,500 shares Expires 2034-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:45 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 500 | $67.38 | $33,692.00 |
DisclosureSEC source: 0000907654-26-000035 · form4.xml · nonDerivative · entry 5 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,377 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.35 to $67.41, inclusive. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:45 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 2,273 | $66.56 | $151,300.65 |
DisclosureSEC source: 0000907654-26-000035 · form4.xml · nonDerivative · entry 4 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,877 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.31 to $67.15, inclusive. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:45 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 4,227 | $65.73 | $277,836.91 |
DisclosureSEC source: 0000907654-26-000035 · form4.xml · nonDerivative · entry 3 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,150 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.31 to $66.29, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:45 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0000907654-26-000035 · form4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:45 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $6.84 | $23,940.00 |
DisclosureSEC source: 0000907654-26-000035 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · derivative · entry 8 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,992 Underlying: Common Stock · 3,500 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · derivative · entry 7 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,563 Underlying: Common Stock · 3,500 shares Expires 2034-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 641 | $41.30 | $26,473.30 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · nonDerivative · entry 6 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,377 F5 · kind: These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.